Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 429

Similar articles for PubMed (Select 11090543)

1.

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL.

Circ Res. 2000 Nov 24;87(11):992-8.

2.

Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.

Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL.

Mol Pharmacol. 2000 May;57(5):1011-20.

3.

Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.

Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL.

Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8. doi: 10.1111/j.1742-7843.2008.00213.x. Epub 2008 Feb 29.

PMID:
18312493
4.

14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.

Fang X, Hu S, Xu B, Snyder GD, Harmon S, Yao J, Liu Y, Sangras B, Falck JR, Weintraub NL, Spector AA.

Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H55-63. Epub 2005 Aug 19.

5.

Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.

Sharkey LC, Radin MJ, Heller L, Rogers LK, Tobias A, Matise I, Wang Q, Apple FS, McCune SA.

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):47-57. doi: 10.1016/j.taap.2013.08.012. Epub 2013 Aug 28.

PMID:
23993975
6.

Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.

Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL.

Drug Metab Dispos. 2007 Jul;35(7):1126-34. Epub 2007 Apr 12.

7.

5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.

Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC.

Hypertension. 2003 Oct;42(4):548-54. Epub 2003 Aug 25.

8.

Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.

Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, Spector AA.

J Biol Chem. 2001 May 4;276(18):14867-74. Epub 2001 Feb 7.

9.

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD.

Hypertension. 2002 Feb;39(2 Pt 2):690-4.

10.

Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.

Sellers KW, Sun C, Diez-Freire C, Waki H, Morisseau C, Falck JR, Hammock BD, Paton JF, Raizada MK.

FASEB J. 2005 Apr;19(6):626-8. Epub 2005 Jan 19.

11.

Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats.

Jiang H, Quilley J, Doumad AB, Zhu AG, Falck JR, Hammock BD, Stier CT Jr, Carroll MA.

Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H1990-6. doi: 10.1152/ajpheart.01267.2010. Epub 2011 Mar 11.

12.

Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.

Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F765-72. doi: 10.1152/ajprenal.00201.2011. Epub 2011 Jul 13.

13.

Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD.

J Am Soc Nephrol. 2004 May;15(5):1244-53.

14.

Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.

Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, Hammock BD, Spector AA.

Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2412-20. Epub 2004 Jul 29.

15.

Epoxyeicosatrienoic acid-mediated renal vasodilation to arachidonic acid is enhanced in SHR.

Pomposiello SI, Carroll MA, Falck JR, McGiff JC.

Hypertension. 2001 Mar;37(3):887-93.

16.

Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice.

Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves ACh, Huang Y, Luft FC, Gollasch M.

Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):54-60. doi: 10.1161/ATVBAHA.108.171298. Epub 2008 Oct 16.

17.

Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase.

Widstrom RL, Norris AW, Van Der Veer J, Spector AA.

Biochemistry. 2003 Oct 14;42(40):11762-7.

PMID:
14529287
18.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20. doi: 10.1016/j.bmcl.2009.07.138. Epub 2009 Aug 6.

PMID:
19682899
19.

Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis.

Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, Capdevila JH.

Arch Biochem Biophys. 1995 Jan 10;316(1):443-51.

PMID:
7840649
20.

Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.

Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC.

Circ Res. 1998 Nov 2;83(9):932-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk